Intuitive Surgical, Inc.
ISRG Healthcare Medical - Instruments & Supplies NASDAQ
$575.34
+$6.71 (+1.18%)
Open: $569.50 | High: $576.88 | Low: $569.43 | Prev Close: $568.63
Market Cap: $205.53B
Volume: 1.1M | Avg: 2.3M
Last updated: December 05, 2025 at 10:04 PMInvestment Rating
Neutral
Overall Score: 60/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 590
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | 75.90 |
| P/B Ratio | 12.12 |
| P/S Ratio | 21.38 |
| EPS | $7.58 |
| Beta | 1.69 |
| Shares Outstanding | 357.23M |
| 52-Week High | $616.00 |
| 52-Week Low | $425.00 |
| SMA 50 | $513.20 |
| SMA 200 | $508.86 |
| Next Earnings | January 22, 2026 09:00 PM ET |
Financial Ratios
| Gross Margin | 66.4% |
| Operating Margin | 29.3% |
| Net Margin | 28.6% |
| ROE | 16.1% |
| ROA | 14.2% |
| Debt/Equity | 0.00 |
| Current Ratio | 4.73 |
| Quick Ratio | 3.74 |
Balance Sheet
| Total Assets | $18.84B |
| Total Liabilities | $2.31B |
| Total Equity | $16.43B |
| Cash | $2.03B |
| Total Debt | $146.00M |
| Net Debt | $-1,881,400,000 |
Income Statement
| Revenue | $8.35B |
| Gross Profit | $5.63B |
| Operating Income | $2.35B |
| Net Income | $2.32B |
| EBITDA | $2.81B |
| Revenue/Share | $26.95 |
Cash Flow
| Operating CF | $2.42B |
| CapEx | $1.11B |
| Free Cash Flow | $1.30B |
| Book Value/Share | $47.79 |
| Tangible Book/Share | $44.50 |
| Equity/Share | $47.48 |
Technical Indicators
| RSI (14) | 51.72 Neutral |
| MACD |
14.11
Signal: 16.88
|
| Volatility | 26.83% |
| Trading Signal | Bearish |
Performance & Returns
| 1 Year | -5.45% |
| Sharpe Ratio | -0.15 Poor |
| Volatility (Ann.) | 38.08% Moderate |
| ISRG (1Y) | -5.45% |
| S&P 500 (1Y) | +11.86% |
| Alpha (Excess Return) | -17.31% |
Sector Comparison (Healthcare)
| Metric | ISRG | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | 75.9 | 30.43 | 92% |
| P/B Ratio | 12.12 | -0.77 | 90% |
| ROE (%) | 16.08% | 9.69% | 57% |
| Net Margin (%) | 28.58% | 9.73% | 90% |
| Stock Score | 590 | 503.0 | 92% |
| 1Y Return (%) | -5.45% | +4.59% | 32% |
Historical Price Analysis (Last 200 Days)
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ISRG | $575.34 | $569.38 | $571.06 | $564.65 | $513.20 | $508.86 | 51.72 | 14.11 | 26.83% | 1147842 | Weak Short | Price Below SMAs |
Candlestick Patterns
There wasn't any recognizable pattern for the ISRG stock
News Sentiment
| 📊 Ticker | 📰 Headline | 💭 Sentiment | 📡 Source | 🔗 URL |
|---|---|---|---|---|
| ISRG | Medtronic Scores FDA Win As Hugo Surgical Robot Enters 230,000 Urology Procedure Market | Neutral | feeds.benzinga.com | Read More |
| ISRG | Margins Face Tariff Pressure: Is ISRG's Profitability at Risk? | Positive | zacks.com | Read More |
| ISRG | 3 Growth Beasts That Have Beaten the Market in 8 of the Past 10 Years | Positive | fool.com | Read More |
| ISRG | Intuitive Surgical: Da Vinci Delivers, Double-Digit EPS Growth, Golden Cross | Positive | seekingalpha.com | Read More |
| ISRG | Here's Why Intuitive Surgical, Inc. (ISRG) Fell More Than Broader Market | Neutral | zacks.com | Read More |
Company Information
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its surgical systems; progressive learning pathways to support the use of its technology; a complement of services to its customers, including support, installation, repair, and maintenance; and integrated digital capabilities providing unified and connected offerings, streamlining performance for hospitals with program-enhancing insights. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.
| CEO | David J. Rosa |
| Employees | 15638 |
| Country | US |
| IPO Date | 2000-06-16 |
| Exchange | NASDAQ |
| Website | https://www.intuitive.com |
| Sector | Healthcare |
| Industry | Medical - Instruments & Supplies |
Similar Stocks (Healthcare - Medical - Instruments & Supplies)
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category